Join us for an interactive session that combines regulatory updates, case studies, and a live Q&A. You’ll gain exclusive insights on the latest GARD® data from SenzaGen’s research and industry […]
Exciting news from the SenzaGen Group! Our Group company VitroScreen has recently validated and implemented the in vitro skin sensitization assay EpiSensA (OECD TG 442D). With this new achievement, we […]
The SenzaGen team is ready to connect at this year’s SOT in Orlando, USA! Join us for an interactive program featuring a hosted session and multiple poster presentations showcasing advancements […]
Redeye interviewed the CEO of SenzaGen, Peter Nählstedt, where they discussed the company’s recently released Q3 2024 report. View CEO interview
Penser Access by Carnegie har intervjuat SenzaGens VD, Peter Nählstedt, i samband med bolagets Q3-rapport. Intervjun behandlar utvecklingen under kvartalet, bolagets syn på det aktuella marknadsläget samt framtidsutsikter och strategiska […]
We are excited to announce that SenzaGen has secured financing to accelerate portfolio expansion within non-animal testing.With this, we are poised for an even brighter growth path. The funding enables […]
SenzaGen is on a growth path. Watch CEO Peter Nählstedt present the company at BioStock Life Science Summit 2023. #Summit #BioStockSWE
Click image to view the newsletter in browser.
Click image to view the newsletter in browser.
We are happy to team up with Oroxcell by welcoming them as distributor of our innovative GARD® test portfolio. Based near Paris, France, Oroxcell is an established CRO in the […]
